financetom
Business
financetom
/
Business
/
RBC Reviews Trisura's Q1
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RBC Reviews Trisura's Q1
May 3, 2024 9:11 AM

11:38 AM EDT, 05/03/2024 (MT Newswires) -- Trisura ( TRRSF ) reported Q1/24 operating EPS of $0.68 vs. $0.57 in Q1/23, slightly ahead of RBC's $0.65 estimate and $0.66 consensus estimate. The modest upside was in both the Canada and U.S. segments.

The Canadian unit delivered an impressive result in the quarter across the board with net written premium growth up more than

30% in the quarter., writes RBC. Net written premium growth exceeded expectations in the U.S. segment, although earned premiums were a bit shy of RBC's forecast.

Trisura ( TRRSF ) is rated Outperform, with a $44 target at RBC.

Price: 45.55, Change: +2.92, Percent Change: +6.85

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Milestone Pharmaceuticals Says FDA Accepted for Review Cardamyst Nasal Spray Resubmission
Milestone Pharmaceuticals Says FDA Accepted for Review Cardamyst Nasal Spray Resubmission
Jul 11, 2025
07:02 AM EDT, 07/11/2025 (MT Newswires) -- Milestone Pharmaceuticals ( MIST ) said Friday the US Food and Drug Administration has accepted for review its response to issues raised in the regulator's complete response letter for Cardamyst nasal spray. The FDA has set a target action date of Dec. 13. Cardamyst nasal spray is a novel investigational therapy for the...
Signing Day Sports Advances Business Combination With BlockchAIn Digital Infrastructure
Signing Day Sports Advances Business Combination With BlockchAIn Digital Infrastructure
Jul 11, 2025
07:02 AM EDT, 07/11/2025 (MT Newswires) -- Signing Day Sports ( SGN ) said Friday it has submitted a draft registration statement with the US Securities and Exchange Commission for a business combination agreement with BlockchAIn Digital Infrastructure. The closing of the transaction, announced in May, is subject to approval of Signing Day Sports ( SGN ) shareholders and approval...
Trump's $100 million crypto mystery man
Trump's $100 million crypto mystery man
Jul 11, 2025
(Reuters) -Of all the riddles wrapped in the digital wallets sending funds to President Donald Trump's World Liberty Financial crypto business, a little-known entity last month became the biggest.  A venture calling itself Aqua 1 Foundation and saying it is based in the United Arab Emirates announced in late June it had bought $100 million worth of World Liberty's crypto...
Copyright 2023-2026 - www.financetom.com All Rights Reserved